Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation.
The aim of this study was to evaluate the effects of atorvastatin on left atrial (LA) function in paroxysmal atrial fibrillation patients. Fifty-eight paroxysmal atrial fibrillation patients were divided into two groups (treatment and control groups). The echocardiography parameters, including LA active emptying volume (LAAEV), LA active emptying fraction, LA maximum volume, LA total emptying volume, LA total emptying fraction, and LA ejection force (LAEF), were measured before treatment, and then 12 and 18 months after treatment. Compared to pre-treatment levels, the parameters reflecting LA pump function, such as LAAEV and LAEF, decreased significantly in treatment groups 12 months after treatment (P < 0.05). LAAEV and LAEF significantly increased 18 months after treatment (P < 0.05), and the indicators reflecting LA reservoir function, such as maximum volume, total emptying volume, and total emptying fraction increased significantly 18 months after treatment (P < 0.05). Compared with pre-treatment levels, LAAEV and LAEF decreased significantly 18 months after treatment in the control group (P < 0.05). These results demonstrated that long-term atorvastatin treatment could ameliorate the function of the atrium sinistrum.
Pacing and Electrophysiology Department, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Y D
YD
Li
B P
BP
Tang
F
F
Guo
J X
JX
Li
W
W
Han
Q
Q
Tang
Y Y
YY
Zhang
D000328:Adult; D000069059:Atorvastatin; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology*; D016279:Atrial Function, Left / Q000187:drug effects*; D004452:Echocardiography / Q000187:drug effects; D005260:Female; D006325:Heart Atria / Q000503:physiopathology; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*
D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin